Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

1,461 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Phase II Study of the Liposomal Formulation of Eribulin (E7389-LF) in Combination with Nivolumab: Results from the Gastric Cancer Cohort.
Kawazoe A, Yamamoto N, Sugimoto N, Kawakami H, Oshima T, Yamaguchi K, Hino K, Hirao M, Kurokawa Y, Kawakami T, Tsuda M, Hara H, Kaname S, Matsuoka D, Otake Y, Yasuda K, Takase T, Takashima S, Semba T, Muro K. Kawazoe A, et al. Among authors: kawakami h, kawakami t. Clin Cancer Res. 2024 Apr 1;30(7):1264-1272. doi: 10.1158/1078-0432.CCR-23-1768. Clin Cancer Res. 2024. PMID: 38295160 Free PMC article. Clinical Trial.
A phase I dose-escalation study of eribulin and S-1 for metastatic breast cancer.
Sakiyama T, Tsurutani J, Iwasa T, Kawakami H, Nonagase Y, Yoshida T, Tanaka K, Fujisaka Y, Kurata T, Komoike Y, Nishio K, Nakagawa K. Sakiyama T, et al. Among authors: kawakami h. Br J Cancer. 2015 Mar 3;112(5):819-24. doi: 10.1038/bjc.2015.10. Epub 2015 Feb 5. Br J Cancer. 2015. PMID: 25654665 Free PMC article. Clinical Trial.
Randomized, Open-Label Phase II Study Comparing Capecitabine-Cisplatin Every 3 Weeks with S-1-Cisplatin Every 5 Weeks in Chemotherapy-Naïve Patients with HER2-Negative Advanced Gastric Cancer: OGSG1105, HERBIS-4A Trial.
Kawakami H, Takeno A, Endo S, Makari Y, Kawada J, Taniguchi H, Tamura S, Sugimoto N, Kimura Y, Tamura T, Fujitani K, Sakai D, Shimokawa T, Kurokawa Y, Satoh T. Kawakami H, et al. Oncologist. 2018 Dec;23(12):1411-e147. doi: 10.1634/theoncologist.2018-0175. Epub 2018 Aug 16. Oncologist. 2018. PMID: 30115736 Free PMC article. Clinical Trial.
Safety and efficacy of pembrolizumab in combination with S-1 plus oxaliplatin as a first-line treatment in patients with advanced gastric/gastroesophageal junction cancer: Cohort 1 data from the KEYNOTE-659 phase IIb study.
Kawazoe A, Yamaguchi K, Yasui H, Negoro Y, Azuma M, Amagai K, Hara H, Baba H, Tsuda M, Hosaka H, Kawakami H, Oshima T, Omuro Y, Machida N, Esaki T, Yoshida K, Nishina T, Komatsu Y, Han SR, Shiratori S, Shitara K. Kawazoe A, et al. Among authors: kawakami h. Eur J Cancer. 2020 Apr;129:97-106. doi: 10.1016/j.ejca.2020.02.002. Epub 2020 Mar 4. Eur J Cancer. 2020. PMID: 32145474 Free article. Clinical Trial.
Phase II study of 5-fluorouracil-leucovorin plus bevacizumab for chemotherapy-naïve older or frail patients with metastatic colorectal cancer (OGSG 0802).
Ohta T, Kato T, Kawakami H, Miyake Y, Goto M, Iwamoto S, Otsuji T, Nakamura M, Sugimoto N, Okamura S, Kotaka M, Tsujie M, Tokunaga Y, Mishima H, Hata T, Shimokawa T, Kurokawa Y, Satoh T. Ohta T, et al. Among authors: kawakami h. Int J Clin Oncol. 2020 Jul;25(7):1291-1298. doi: 10.1007/s10147-020-01656-3. Epub 2020 Mar 26. Int J Clin Oncol. 2020. PMID: 32219630 Clinical Trial.
Trastuzumab Deruxtecan in Previously Treated HER2-Positive Gastric Cancer.
Shitara K, Bang YJ, Iwasa S, Sugimoto N, Ryu MH, Sakai D, Chung HC, Kawakami H, Yabusaki H, Lee J, Saito K, Kawaguchi Y, Kamio T, Kojima A, Sugihara M, Yamaguchi K; DESTINY-Gastric01 Investigators. Shitara K, et al. Among authors: kawakami h. N Engl J Med. 2020 Jun 18;382(25):2419-2430. doi: 10.1056/NEJMoa2004413. Epub 2020 May 29. N Engl J Med. 2020. PMID: 32469182 Clinical Trial.
Comparison of S-1-cisplatin every 5 weeks with capecitabine-cisplatin every 3 weeks for HER2-negative gastric cancer (recurrent after S-1 adjuvant therapy or chemotherapy-naïve advanced): pooled analysis of HERBIS-2 (OGSG 1103) and HERBIS-4A (OGSG 1105) trials.
Kawakami H, Fujitani K, Matsuyama J, Akamaru Y, Tamura S, Endo S, Kimura Y, Makari Y, Tamura T, Sugimoto N, Sakai D, Tsujinaka T, Goto M, Kurokawa Y, Shimokawa T, Satoh T; Osaka Gastrointestinal Cancer Chemotherapy Study Group (OGSG). Kawakami H, et al. Int J Clin Oncol. 2020 Sep;25(9):1635-1643. doi: 10.1007/s10147-020-01711-z. Epub 2020 Jun 3. Int J Clin Oncol. 2020. PMID: 32494981 Clinical Trial.
Docetaxel plus S-1 versus cisplatin plus S-1 in unresectable gastric cancer without measurable lesions: a randomized phase II trial (HERBIS-3).
Kurokawa Y, Matsuyama J, Nishikawa K, Takeno A, Kimura Y, Fujitani K, Kawabata R, Makari Y, Terazawa T, Kawakami H, Sakai D, Shimokawa T, Satoh T. Kurokawa Y, et al. Among authors: kawakami h. Gastric Cancer. 2021 Mar;24(2):428-434. doi: 10.1007/s10120-020-01112-1. Epub 2020 Aug 10. Gastric Cancer. 2021. PMID: 32779034 Clinical Trial.
A phase II trial of dose-reduced nab-paclitaxel for patients with previously treated, advanced or recurrent gastric cancer (OGSG 1302).
Tamura S, Taniguchi H, Nishikawa K, Imamura H, Fujita J, Takeno A, Matsuyama J, Kimura Y, Kawada J, Hirao M, Hirota M, Fujitani K, Kurokawa Y, Sakai D, Kawakami H, Shimokawa T, Satoh T. Tamura S, et al. Among authors: kawakami h. Int J Clin Oncol. 2020 Dec;25(12):2035-2043. doi: 10.1007/s10147-020-01768-w. Epub 2020 Sep 14. Int J Clin Oncol. 2020. PMID: 32926227 Free PMC article. Clinical Trial.
1,461 results